Update shared on 01 Nov 2025
Narrative Update on Sotera Health
Analysts have maintained their price target for Sotera Health at $17.00 per share. They cite unchanged growth expectations and financial metrics that support the previous valuation.
What's in the News
- Sotera Health Company raised its earnings guidance for full year 2025, increasing expected net revenues to 4.5% to 6.0% growth on a constant currency basis (Key Developments).
- The company completed a follow-on equity offering of $307 million, issuing 20,000,000 shares of common stock at $15.35 per share (Key Developments).
- Sotera Health filed an additional follow-on equity offering valued at $323.2 million for 20,000,000 shares at $16.16 per share (Key Developments).
- Multiple classes of company securities, including RSU, PSU, options, and common stock, are subject to lock-up agreements that will end on October 19, 2025 (Key Developments).
Valuation Changes
- Fair Value: Remained unchanged at $17.00 per share.
- Discount Rate: Increased very slightly from 8.31% to 8.32%.
- Revenue Growth: Stable at 6.39% year over year.
- Net Profit Margin: Unchanged at 23.20%.
- Future P/E: Edged up minimally from 19.66x to 19.67x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.